RTaylorRipley Profile Banner
R. Taylor Ripley, M.D. Thoracic Surgeon Profile
R. Taylor Ripley, M.D. Thoracic Surgeon

@RTaylorRipley

Followers
2K
Following
390
Media
158
Statuses
581

Meyer-DeBakey Chair in Investigative Surgery; Director, Mesothelioma, Thoracic Research, Clinical Trials @BCM_Surgery; Editor, Seminars JTCVS

Houston, TX
Joined May 2016
Don't wanna be here? Send us removal request.
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
24 days
Targeting two proteins in the BCL-2 pathway was specific to the mitochondria @bcmhouston @BCMFromtheLabs @BCM_Surgery @BCMCancerCenter #mesothelioma
1
1
6
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
24 days
The mitochondria with highly damaged by targeting two proteins in the mitochondria @bcmhouston @BCMFromtheLabs @BCM_Surgery @BCMCancerCenter #mesothelioma
0
0
1
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
24 days
Actively enrolling in NEMO for patients with surgically resectable pleural #mesothelioma @BCM_Surgery @bcmhouston @BCMCancerCenter @BCMFromtheLabs 713-798–LUNG (6376) or lungsched@bcm.edu
0
0
2
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
11 months
Congrats, Dr Davis! Well deserved. Looking forward to seeing years of outstanding work.
@JeremyLDavisMD
Jeremy L. Davis MD, FACS
11 months
Thanks for the warm welcome! @UMMC @UMmedschool
0
0
12
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
11 months
Actively enrolling in NEMO for patients with #mesothelioma in which patients receive three cycles of immunotherapy or chemoimmunotherapy followed by surgery followed by one year of immunotherapy @BCM_Surgery @bcmhouston @BCMCancerCenter @BCMFromtheLabs 713-798–LUNG (6376).
0
3
20
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
11 months
Our peer-reviewed, pre-print response to MARS2 for #surgery #mesothelioma online @AATSJournals @AATSHQ. Thank you and congratulations to all the authors who wrote this article. Going to MARS May Shorten Our Patient’s Survival - The Journal of Thoracic and Cardiovascular Surgery
1
6
28
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
1 year
Thank you, Shanda. We have and outstanding team @BCM_Surgery @BCMFromtheLabs @bcmhouston @BCMCancerCenter focused on translating our scientific work to patient care. @ShandaBlackmon @DrRosengart. #mesothelioma #esophagealcancer #lcmc
@ShandaBlackmon
Shanda Blackmon, MD, MPH
1 year
@BCM_Surgery⁩ ⁦@BCMLungInst⁩ busy Friday as Dr. Taylor Ripley creates an inclusive and inspiring environment in his weekly lab meeting. Biobanking, novel therapy, basic science, innovation- all being discussed.
1
1
17
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
1 year
Agree. Dysphasia is as sensitive as EUS. Lower stages uncommon and risks of nodal positivity is high.
0
0
12
@SXC71
SubhasisChatterjeeMD
1 year
Attention @TXMedCenter physicians, APPs, RNs, and trainees -cutting edge critical care from leaders; practical advice to take back to your unit @BCM_Surgery @BCMDeptMedicine @BCMAnesthesia @Texas_Heart
@Jose_Diaz_Gomez
José L. Díaz-Gómez, MD, MAS, FCCM, FASE, NCC(UCNS)
1 year
@SXC71 and I invite you to join us #ACC2024 A fantastic blend of local and national expert speakers under a unique presentation format. Here are the ones coming from other states/countries. https://t.co/S869HWi7y0
0
4
11
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
1 year
In Ripley-Xu Lab, the Mitochondria Continue to Knock-Out Mesothelioma, Lung and Esophageal Cancer @BCM_Surgery @bcmhouston @BCMCancerCenter @BCMFromtheLabs @BCM_Thoracic Thank you @ScottHolmesCMI for the image!
0
2
14
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
1 year
Monica Vilchis exemplifies excellence @bcmhouston @BCM_Surgery @BCMFromtheLabs @BCM_Thoracic @DrRosengart @ShandaBlackmon @DrShawnGroth. She is instrumental in the multiple clinical trials in our division of thoracic surgery!
@TSOG_ClinTrials
Thoracic Surgery Oncology Group (TSOG)
1 year
#StaffSpotlight Monica Vilchis is a CR Supervisor @BCM_Thoracic working on the TSOG 101 ctDNA, TSOG 102 GGO, & TSOG 104 Mesothelioma studies. Her emphasis on timely & effective communication makes her a consummate team player and an asset to the TSOG team. @BCM_Surgery
1
5
21
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
1 year
Enrollment is underway for NEMO with 3 Cycles Durva/Treme w/wo Cis/Peme followed by Surgery, followed by 1-Yr Durvalumab. @BCM_Surgery @bcmhouston @BCMCancerCenter @BCM_Thoracic for patients with #Mesothelioma. @AstraZeneca @AATSHQ. 713-798-6376 or lungsched@bcm.edu
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
1 year
Actively enrolling in NEMO for patients with #mesothelioma in which patients receive three cycles of immunotherapy or chemoimmunotherapy followed by surgery followed by one year of immunotherapy @BCM_Surgery @bcmhouston @BCMCancerCenter @BCMFromtheLabs 713-798–LUNG (6376).
0
3
12
@AATSHQ
AATS
1 year
New in Seminars in #Thoracic and #Cardiovascular Surgery: Surgical Outcomes After Reconstruction of the Aortomitral Curtain. See the recommendations based on the researcher's conclusions: https://t.co/zAGocN6neT @KeckMedicineUSC @KECKSchool_USC
0
3
13
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
1 year
Actively enrolling in NEMO for patients with #mesothelioma in which patients receive three cycles of immunotherapy or chemoimmunotherapy followed by surgery followed by one year of immunotherapy @BCM_Surgery @bcmhouston @BCMCancerCenter @BCMFromtheLabs 713-798–LUNG (6376).
0
1
8
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
1 year
Mapping Clinical Trial Activation @BCM_Surgery @bcmhouston @BCMFromtheLabs. The Office of Surgical Research is tirelessly working to streamline the processes.
0
1
13
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
1 year
Ripley-Xu lab at @BCM_Surgery @bcmhouston @BCMFromtheLabs growing rapidly to study mechanisms underlying therapeutic resistance! Clean and ready to go!
1
3
23
@RTaylorRipley
R. Taylor Ripley, M.D. Thoracic Surgeon
1 year
Now enrolling in NEMO for patients with resectable pleural #mesothelioma @bcmhouston @BCM_Surgery @BCMCancerCenter @BCM_Thoracic @BCMFromtheLabs Study on Durvalumab, Tremelimumab and chemotherapy for Mesothelioma | BCM
0
1
6